Metformin, a drug used for patients with type 2 diabetes, as well as other AMPK activators, reportedly suppress tumorigenicity and YAP activity via AMPK activation in vitro and in vivo [142]. The gene discussed is PRKAA2; the disease is type 2 diabetes mellitus.